Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921503 | 1.00 | NFE2L2 (0.51) | NFE2L2L3MBTL1TRPA1ALDH1A1LMNA | |
| SCHEMBL733566 | 0.80 | — | — | |
| SCHEMBL30983654 | 0.77 | — | — | |
| SCHEMBL2555506 | 0.75 | ALDH1A1 (0.39) | TRPA1ALDH1A1LMNAALOX5MAPK1 | |
| SCHEMBL2555511 | 0.75 | ALDH1A1 (0.39) | TRPA1ALDH1A1LMNAALOX5MAPK1 | |
| SCHEMBL18133615 | 0.75 | CCR1 (0.43) | TRPA1ALDH1A1LMNAALOX5MAPK1 | |
| SCHEMBL74726 | 0.74 | NFE2L2 (0.50) | NFE2L2L3MBTL1PTK2NPC1STAT1 | |
| SCHEMBL74727 | 0.74 | NFE2L2 (0.50) | NFE2L2L3MBTL1PTK2 | |
| SCHEMBL74725 | 0.74 | NFE2L2 (0.50) | NFE2L2L3MBTL1PTK2NPC1STAT1 | |
| SCHEMBL9000499 | 0.72 | NFE2L2 (0.49) | NFE2L2L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| CN-108602809-B | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1(RIPK 1) | 戴纳立制药公司 | 2022-09-30 | — | — | CN | disclosed |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | APTUIT (VERONA) S.R.L. (IT) | 2018-12-13 | — | — | US | disclosed |
| WO-2017096301-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK 1) | DENALI THERAPEUTICS INC. (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | NFE2L2 1767/4885L3MBTL1 2651/4885TRPA1 4105/4885 |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | NFE2L2 1767/4885L3MBTL1 2651/4885TRPA1 4105/4885 |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | NFE2L2 3756/4885L3MBTL1 4764/4885TRPA1 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.